Carmine SELLERI | Projects
Carmine SELLERI Projects
4 Funded projects
Filter
In this study, we aim at investigating the impact of ruxolitinib on marrow fibrosis in MPNs using a well-established 3D in vitro model of BM niche mimicking cell-to-cell contacts and paracrine pathways intercurrent between stromal cells and BMMCs in normal and pathological hematopoiesis.Specific aims: 1. Establishment of a 3D in vitro co-culture model of myelofibrosis.2. Ruxolitinib effects on
Department | Dipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”/DIPMED | |
Principal Investigator | SELLERI Carmine (Project Coordinator) | |
Funding | University funds | |
Cost | 3.505,26 euro | |
Project duration | 31 July 2023 - 31 July 2026 | |
Detail |
Based on findings showing the involvement of proinflammatory low-density granulocytes (LDGs) in activation of type 1 helper responses, and on the predominant role of cytotoxic T cells and type I immune responses in myelodysplastic syndromes (MDS), we hypothesize that LDGs and other immunoregulatory molecules might play an important role in MDS pathophysiology. Specific aims are to: 1) detect and q
Department | Dipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”/DIPMED | |
Principal Investigator | SELLERI Carmine (Project Coordinator) | |
Funding | University funds | |
Funders | Università degli Studi di SALERNO | |
Cost | 3.455,31 euro | |
Project duration | 25 July 2022 - 25 July 2025 | |
Detail |
Studio di marcatori di risposta al trattamento in pazienti con neoplasie ematologiche
Department | Dipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”/DIPMED | |
Principal Investigator | SELLERI Carmine (Project Coordinator) | |
Funding | Finanziamenti da privati italiani | |
Funders | ABBVIE S.R.L. | |
Cost | 38.098,00 euro | |
Project duration | 7 February 2022 - 31 December 2024 | |
Detail |
The discovery of checkpoint inhibitors and engineered T cells has opened a new era in cancer immunotherapy and has changed clinical outcomes of several tumors. T cells expressing chimeric antigen receptors (CARs) are directed against specific tumor-related antigens. To date, only two CD19-specific CAR-T cells have been approved for B-cell acute lymphoblastic leukemia and diffuse large B cell lymph
Department | Dipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”/DIPMED | |
Principal Investigator | SELLERI Carmine (Project Coordinator) | |
Funding | University funds | |
Funders | Università degli Studi di SALERNO | |
Cost | 1.947,43 euro | |
Project duration | 22 November 2021 - 22 November 2024 | |
Detail |
Data source U-GOV dal 1 Gennaio 2013